Evaluation of the Safety and Efficacy of the Omega System for the Treatment of Benign Prostatic Hyperplasia

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The ProArc Medical Omega system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH. During the procedure an implant is delivered into the prostate tissue obstructing the urethra and restricting urine flow. The delivery system uses a static diathermy incision mechanism to make a circumferential incision in the tissue surrounding the prostatic urethra into which the Omega shaped permanent implant is placed. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 50
Healthy Volunteers: f
View:

• Male ≥50 years of age

• Diagnosed with symptomatic benign prostatic hyperplasia (BPH).

• International Prostate Symptom Score (IPSS) \>13.

• Peak flow rate ≤ 12 ml/sec (with voided volume ≥ 125ml).

• Participant understands and is willing to the informed consent form.

• Prostate Volume between 30cc and 80cc.

• Prostate length ≥3cm and ≤5cm

Locations
Other Locations
Israel
Soroka Medical Center
TERMINATED
Beersheba
Carmel Medical Center
TERMINATED
Haifa
Rambam Health Care Campus
TERMINATED
Haifa
New Zealand
Tauranga Urology Research Limited
RECRUITING
Tauranga
Contact Information
Primary
Fay Dan
Fay@proarcmedical.com
+972 54-478-1599
Backup
Gilad Hizkiyahu
gilad@proarcmedical.com
+972 52-241-5544
Time Frame
Start Date: 2023-07-23
Estimated Completion Date: 2026-08
Participants
Target number of participants: 26
Treatments
Experimental: Omega Device
Related Therapeutic Areas
Sponsors
Leads: ProArc Medical

This content was sourced from clinicaltrials.gov